Nava-Castañeda Ángel, Hernández-Orgaz Joaquín, Garnica-Hayashi Lilia, Ansart Alberto, Matus Gonzalo, Tovilla-Canales José Luis
nstituto de Oftalmología Fundación de Asistencia Privada Conde de Valenciana.
Nepal J Ophthalmol. 2018 Jul;10(20):143-150. doi: 10.3126/nepjoph.v10i2.18574.
Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm and it can originate from the conjunctiva and/ or corneal epithelium. Since the rate of recurrence after surgical excision is high, chemotherapeutic and immunotherapeutic agents such as interferon alpha-2b (IFN α-2b) have been used for its treatment.
Our objective is to describe the demographic variables of patients with OSSN treated with IFN α-2b and to describe the outcomes of its use in Mexican patients, treated between 2011 and 2017 at Instituto de Oftalmología Fundación Conde de Valenciana.
This is a non-randomized retrospective interventional case series. We reviewed the files of patients older than 18 years, with clinical and/or histopathological diagnosis of OSSN, treated with IFN α-2b alone or in combination with surgery, with a minimum of 6 months follow-up. We studied demographic variables, such as gender, age, eye affected and associated risks factors; we also studied the type of therapy with interferon (topical, intralesional and/or associated with surgery), time of treatment, time of follow up, recurrences and complications.
A total of 39 patients were included. The mean age of diagnosis was 61 ± 16 years and OSSN was more frequent in males (64.1% of cases). Most of the cases (43.6%) had no identifiable risk factors. The mean time of IFN α-2b treatment was 5 ± 2 months, being higher in the intralesional group (6.5 months) than in the topical group (4.2 months). The clinical resolution with the use of IFN α-2b was evidenced between 0.5 and 10 months, being achieved in 87.1% of the patients.
The use of IFN α-2b is effective for the treatment of OSSN with a high success rate (87.1%) and a low incidence of relapse (5 cases), with no reported complications during follow up.
眼表鳞状上皮肿瘤（OSSN）是最常见的非色素性眼表肿瘤，可起源于结膜和/或角膜上皮。由于手术切除后的复发率较高，已使用化疗和免疫治疗药物，如干扰素α-2b（IFNα-2b）进行治疗。
我们的目的是描述接受IFNα-2b治疗的OSSN患者的人口统计学变量，并描述其在2011年至2017年期间于巴伦西亚伯爵眼科基金会研究所接受治疗的墨西哥患者中的使用结果。
这是一个非随机回顾性干预病例系列。我们查阅了年龄超过18岁、临床和/或组织病理学诊断为OSSN、单独使用IFNα-2b或与手术联合治疗且随访至少6个月的患者档案。我们研究了人口统计学变量，如性别、年龄、患眼和相关危险因素；我们还研究了干扰素治疗类型（局部、病灶内和/或与手术联合）、治疗时间、随访时间、复发情况和并发症。
共纳入39例患者。诊断时的平均年龄为61±16岁，OSSN在男性中更为常见（占病例的64.1%）。大多数病例（43.6%）没有可识别的危险因素。IFNα-2b的平均治疗时间为5±2个月，病灶内治疗组（6.5个月）高于局部治疗组（4.2个月）。使用IFNα-2b后的临床缓解在0.5至10个月之间得到证实，87.1%的患者实现了缓解。
使用IFNα-2b治疗OSSN有效，成功率高（87.1%），复发率低（5例），随访期间未报告并发症。
